Precision Biosciences
Precision Biosciences' revenue fell 50.1% to $34 million in fiscal 2025. Its operating margin was −152.2%, down from −38.1% a year earlier. Free cash flow was −$66 million. The diluted share count rose 86.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Precision Biosciences does
Precision BioSciences is a clinical-stage gene editing company. It has developed a technology it calls ARCUS, a way to cut DNA at a chosen spot in order to insert, remove or cut out a piece of a gene inside the body. It has no approved products.
It is developing two gene editing therapies in clinical trials. PBGENE-HBV is aimed at chronic hepatitis B, a viral infection, by removing viral DNA. PBGENE-DMD is aimed at Duchenne muscular dystrophy, a muscle-wasting disease, by using two ARCUS enzymes delivered in one viral vehicle to cut out part of the defective dystrophin gene. The company says it is designed to potentially improve function for approximately 60% of patients with the disease.
The company formed in 2006. It signed a research and license agreement with Novartis in June 2022 for blood disorders such as sickle cell disease, and on October 31, 2025 it received written notice from Novartis that it was terminating that agreement.
Its biggest risks, as it describes them
- It has lost money since it began and expects more losses.
- It needs substantial additional funding, which could dilute owners or restrict it.
- ARCUS is a new technology, so the time, cost and chance of success of its therapies are hard to predict.
- Other gene editing technologies may prove better than ARCUS.
- Its debt terms may limit what it can do.
Income statement
Precision Biosciences lost money in fiscal 2025: a net loss of $46 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 144 | 190 | 117 | 86 | 116 |
| Debt incl. finance leases | 2 | 22 | — | — | — |
| Net debt (negative means net cash) | −141 | −167 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.4x | — | — | — |
| Interest coverage | −298.3x | −56.1x | −19.6x | −14.7x | −36.7x |
| Current ratio | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
| Quick ratio | 4.5x | 3.3x | 2.7x | 6.3x | 13.3x |
Cash flow
Projections
Project Precision Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $63,215 of Precision Biosciences shares on the open market, and 4 insiders sold $412,359, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Stanley FrankelDirector | Bought | 1,000 | $6.00 | $6,000 | Form 4 |
| Sep 25, 2026 | Geno J GermanoDirector | Bought | 2,609 | $6.28 | $16,385 | Form 4 |
| Sep 25, 2026 | Melinda BrownDirector | Bought | 1,135 | $6.27 | $7,116 | Form 4 |
| Feb 18, 2026 | Michael AmorosoPresident and CEO, Director | Sold plan | 20,559 | $3.84 | $78,947 | Form 4 |
| Feb 18, 2026 | John Alexander KellyChief Financial Officer | Sold plan | 8,149 | $3.84 | $31,292 | Form 4 |
| Feb 18, 2026 | Smith J. JeffersonChief Research Officer | Sold plan | 4,925 | $3.84 | $18,912 | Form 4 |
| Jan 22, 2026 | Michael AmorosoPresident and CEO, Director | Sold plan | 34,799 | $4.17 | $145,112 | Form 4 |
| Jan 21, 2026 | John Alexander KellyChief Financial Officer | Sold plan | 15,213 | $4.03 | $61,308 | Form 4 |
| Jan 21, 2026 | Smith J. JeffersonChief Research Officer | Sold plan | 10,200 | $4.03 | $41,106 | Form 4 |
| Jan 21, 2026 | Dario ScimecaGeneral Counsel and Secretary | Sold plan | 8,854 | $4.03 | $35,682 | Form 4 |
| Dec 16, 2025 | Geno J GermanoDirector | Bought | 3,000 | $4.72 | $14,160 | Form 4 |
| Dec 16, 2025 | Stanley FrankelDirector | Bought | 2,700 | $4.70 | $12,690 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −82.5% | −44.5% | −242.5% |
| Altman Z'' | −8.14 | −8.23 | −7.20 |
| Accruals ratio | 11.5% | 44.3% | 13.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Precision Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Precision Biosciences | FY25 | −50.1% | −152.2% | −192.4% | — | — | — | |
| C4 Therapeutics | FY25 | 1.0% | −320.5% | −276.2% | — | — | 3 | Compare |
| Kymera Therapeutics | FY25 | −16.7% | −891.1% | −597.6% | — | — | — | Compare |
| Voyager Therapeutics | FY25 | −49.5% | −326.6% | −334.5% | — | — | — | Compare |
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 11 | 1,070 | 24 | 116 | 25 | 49 | 69 | 34 |
| Revenue growth | — | 9,731.9% | −97.7% | 375.7% | −78.3% | 94.2% | 41.0% | −50.1% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 45 | 82 | 98 | 115 | 46 | 53 | 60 | 54 |
| Operating income | −48 | −87 | −110 | −39 | −62 | −44 | −26 | −52 |
| Net income | −46 | −93 | −109 | −31 | −112 | −61 | 7 | −46 |
| Diluted EPS (US$) | −87.60 | −66.30 | −62.70 | −15.60 | −38.10 | −15.96 | 1.04 | −3.56 |
| Diluted shares (millions) | 0 | 1 | 2 | 2 | 3 | 4 | 7 | 13 |
| Cash flow | ||||||||
| Cash from operations | −52 | −71 | −87 | −11 | −46 | −84 | −58 | −66 |
| Capital expenditure | 14 | 25 | 5 | 5 | 3 | 2 | 0 | 0 |
| Free cash flow | −66 | −96 | −92 | −16 | −49 | −86 | −59 | −66 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 9 | 14 | 16 | 19 | 14 | 13 | 10 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 103 | 181 | 90 | 144 | 190 | 117 | 86 | 116 |
| Debt incl. finance leases | — | — | — | 2 | 22 | — | — | — |
| Total assets | 139 | 235 | 150 | 212 | 238 | 160 | 136 | 154 |
| Total liabilities | 99 | 97 | 106 | 120 | 178 | 141 | 80 | 62 |
| Shareholders' equity | 40 | 138 | 44 | 91 | 60 | 19 | 56 | 92 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | −440.2% | −8.2% | −452.2% | −34.1% | −248.3% | −89.8% | −38.1% | −152.2% |
| Net margin | −423.0% | −8.7% | −448.9% | −26.5% | −444.8% | −125.8% | 10.4% | −133.4% |
| Free cash flow margin | −606.5% | −8.9% | −380.6% | −13.8% | −195.5% | −176.6% | −85.4% | −192.4% |
| Rule of 40 (growth + FCF margin) | — | 9,722.9% | −478.3% | 361.9% | −273.8% | −82.5% | −44.5% | −242.5% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −104.2% | −119.3% | −45.1% | −147.3% | −154.7% | 19.1% | −61.5% |
| Return on assets | — | −49.7% | −56.6% | −16.9% | −49.6% | −30.8% | 4.8% | −31.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |